4576 — D.Western Therapeutics Institute Income Statement
0.000.00%
Last trade - 00:00
- ¥3bn
- ¥2bn
- ¥428m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 581 | 356 | 414 | 448 | 428 |
Cost of Revenue | |||||
Gross Profit | 555 | 339 | 394 | 421 | 392 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 463 | 621 | 586 | 898 | 1,257 |
Operating Profit | 117 | -266 | -172 | -450 | -829 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 110 | -290 | -160 | -440 | -827 |
Provision for Income Taxes | |||||
Net Income After Taxes | 108 | -291 | -161 | -442 | -828 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 133 | -276 | -149 | -430 | -812 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 133 | -276 | -149 | -430 | -812 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.07 | -10.2 | -5.08 | -11.3 | -24.9 |
Dividends per Share |